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Osteoarthritis (OA) is the most common 
chronic joint disorder, is characterized by 
local inflammation and joint structural 
change, and is associated with painful 
symptoms and loss of function leading 
to considerable impairment of quality 
of life1. Globally, hip and knee OA are 
leading contributors to disability in terms 
of years lived with disability1,2. With 
population ageing and the increasing 
prevalence of obesity across the globe, it is 
widely accepted that the burden of OA 
will continue to increase3, leading to an 
increased strain on health- care systems. 
Given the current absence of effective 
disease- modifying treatments for knee OA, 
attention has turned to providing effective 
guidance on the medical management 
of OA; over the past decade, several sets of 
recommendations have been published4–9. 
Clinical practice guidelines help assist 
decision- making and are therefore a vital 
source of information for health- care 
providers.
NSAIDs and intra- articular corticosteroid 
injections, with joint replacement surgery 
recommended for more severe cases. While 
knee joint replacement has been shown 
to be effective in the management of knee 
OA symptoms18, this surgery might not be 
suitable for all patients as up to 20% report 
dissatisfaction and/or persistent symptoms 
postoperatively19,20. Furthermore, knee 
replacement is conventionally performed 
in end- stage disease18, after years of painful 
symptoms and loss of function and despite 
correctly conducted medical treatment.
In 2014, the European Society for Clinical 
and Economic Aspects of Osteoporosis, 
Osteoarthritis and Musculoskeletal Diseases 
(ESCEO) published recommendations 
for the management of knee OA, which 
summarized expert opinion and the most 
relevant, high- quality data6 and outlined 
a staged treatment algorithm to help 
assist health- care providers in prioritizing 
treatments6. Similarly, the Osteoarthritis 
Research Society International (OARSI), 
which has a history of publishing highly 
cited guidelines for OA21–23, published 
recommendations in 2014 that also 
outlined an algorithm for the non- surgical 
management of knee OA4. In 2019, both of 
these international organizations updated 
their recommendations for the non- surgical 
management of knee OA16,17. In November 
2019, a working group comprising selected 
authors of the 2019 OARSI (N.K.A, R.R.B., 
I.K.H. and T.E.M.) and ESCEO (N.K.A., 
O.B., C.C. and J.- Y.R.) publications as well 
as independent members (T.A.P., M.C.H. 
and A.M.) convened and jointly reviewed 
these latest guidelines. In this Perspective 
article, the members of that working group 
highlight the similarities and differences 
between the treatment algorithms and 
the methodological approaches used to 
formulate recommendations in the OARSI 
and ESCEO guidelines.
Comparison of aims and objectives
The membership of OARSI, an international 
not- for- profit research society, comprises 
both health- care professionals and 
researchers focused on the prevention 
and treatment of OA. OARSI supports 
the international growth of OA- related 
research leading to the dissemination 
of expert resources and knowledge. 
Recommendations for OA treatment are 
often separated into non- pharmacological, 
pharmacological and surgical interven-
tions10,11, as well as categorized by disease 
severity and joint site. Other variances in 
treatment guidelines include the target 
readership (for example, some taking a more 
patient- centred approach) and geographical 
focus (international versus national). These 
differences have led to some confusion,  
evidenced by the limited uptake of published 
guidelines by patients12 and within primary 
and secondary care13,14.
Most guidelines, however, agree in 
their core treatment recommendations for 
knee OA15, which include the provision of 
education, physical therapy and encouraging 
weight loss. The guidelines then typically 
either outline a sequential, staged approach 
to the management of knee OA beyond 
core treatments6,16,17 or outline treatment 
recommendations by disease and/or 
comorbidity group4,7,9. Treatment typically 
includes the use of analgesics, including 
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ESCEO, a not- for- profit organization that 
operates within Europe, specializes in the 
provision of care and musculoskeletal 
research through supporting networks of 
academic scientists, prescribing physicians, 
not- for- profit organizations, regulatory 
authorities and corporate partners; ESCEO 
is tasked with providing practitioners with 
the most current, clinical, and economic 
evidence- based information to assist in 
the delivery of care. Both the 2019 OARSI 
and ESCEO guidelines were constructed to 
provide a practical algorithm to help guide 
clinicians in their decision- making for the  
management of knee OA16,17. In addition, 
both guidelines aimed to deliver 
patient- centred recommendations.
The OARSI guidelines17 update 
and expand upon previously reported 
OARSI guidelines4. Similarly, the 2019 
ESCEO guidelines16 sought to update 
their previously published algorithm6 by 
including new evidence published since 
2014. Whereas the 2019 ESCEO guidelines 
focus only on the evaluation of treatments 
for knee OA, the OARSI guidelines include 
recommendations for knee OA, hip OA 
and polyarticular OA. Furthermore, OARSI 
exclusively formulated recommendations 
for the non- surgical management of 
knee OA whereas ESCEO developed 
recommendations for both non- surgical 
and surgical treatments. In this article, 
we focus exclusively on guidelines related 
to the non- surgical management of knee 
OA as it is generally regarded that surgical 
intervention remains the most effective 
and cost- effective treatment modality for 
end- stage disease18,24,25.
Comparison of the methodologies
In this section, we examine the similarities 
and differences between the methods 
used by OARSI and ESCEO to develop the 
treatment algorithms and recommendations 
in their respective 2019 guidelines. Briefly, 
the methods used were largely similar, with 
both organizations using well- characterized 
procedures for the reporting of the 
guidelines. However, key differences exist 
in the constitution of the panels, literature 
search strategies, voting procedures and 
scaling of the treatment recommendations, 
which need to be carefully considered. The 
methodological similarities and differences 
are summarized in Table 1.
Assessing quality of evidence
The working groups that developed the 
2019 OARSI and ESCEO guidelines both 
followed the Grading of Recommendations, 
Assessment, Development and Evaluations 
(GRADE)26 methodology, which combines 
an objective review of the literature with 
expert consensus. OARSI evaluated the 
methodological rigour of meta- analyses and 
systematic reviews using the Assessment 
of Multiple Systematic Reviews Tool and 
randomized controlled trials using the 
Table 1 | Comparison of methodologies used to develop recommendations for the non- surgical management of knee oa
method oaRSI eSCeo
Objectives To perform an updated review of the literature, to assess 
the harms and benefits of 67 pre- specified non- surgical 
treatments for knee OA and to develop a treatment 
algorithm for the non- surgical management of knee OA
To perform an updated review of the literature, to assess the 
efficacy of a selected group of medications and to develop a set 
of treatment recommendations for the surgical and non- surgical 
management of knee OA in patient- specific scenarios
Panels The OARSI working group included specialists in 
rheumatology, orthopaedics, primary care, pharmacology, 
sports medicine, clinical epidemiology, evidence- based 
medicine, rehabilitation and physical therapy, as well as 
patient representatives
A core expert panel of six members supervised the project; 
the voting panel comprised 13 members, and five individuals 
made up the literature review panel
The ESCEO working group included specialists in rheumatology, 
rehabilitation, orthopaedics, clinical epidemiology, geriatrics, 
pharmacology, public health and health economics, as well as 
patient representatives
A single panel comprised 18 members, of whom four conducted 
the literature search
Literature search Databases searched included Medline, EMBASE, Cochrane 
databases, PubMed, Google Scholar and the reference lists 
of relevant systematic reviews and meta- analyses
Modified GRADE criteria were used to rate the quality of 
evidence; the literature search covered the period until 
December 2017 (with no start date; the search was updated 
on 12 July 2018)
Search terms included, but were not limited to, 
‘osteoarthritis’, ‘arthrosis’, ‘randomized controlled trials’, 
‘crossover’, ‘controlled trial’, ‘double- blind’, ‘single- blind’, 
‘arthroscopy’ and ‘arthroplasty’
Meta- analyses of the reviewed manuscripts were performed
Databases searched included Medline, EMBASE and Cochrane 
databases
GRADE criteria were used to rate the quality of evidence
The literature search covered the period included in the previous 
guidelines (that is, 2000 to February 2014) plus a new search that 
covered publications from 2014 to 30 September 2018
Search terms included keywords and controlled terms for the 
study types and OA; the exact search strategies used were not 
published
Meta- analysis was not performed
Voting procedure Voting on recommendations was carried out online using an 
anonymous survey application
In stage 1, the initial vote was to select core treatmentsa 
from a pre- specified list of candidates
Stage 2 consisted of three further voting rounds
Votes were submitted by e- mail and were anonymous;  
the number of voting rounds was not reported
Strength of 
recommendations
Recommendations were determined to be ‘strong’ (if ≥75% 
of the panel voted either for or against) or ‘conditional’  
(if 26–74% of the panel voted for or against and vice versa)
Core treatmentsa were given a strong recommendation  
by default
Consensus was defined as ≥75% of the panel members 
voting either ‘strongly’ or ‘weakly’ in favour of or against a 
recommendation; the strength of the recommendation was 
determined to be ‘strong’ rather than ‘weak’ if ≥75% of the panel 
rated a recommendation as ‘strong’
GRADE, Grading of Recommendations Assessment, Development and Evaluation; ESCEO, European Society for Clinical and Economic Aspects of Osteoporosis, 
Osteoarthritis and Musculoskeletal Diseases; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International. aCore treatments were defined as treatments 
appropriate for use by the majority of patients in nearly any scenario and deemed to be safe for use in conjunction with first- line and second- line treatments.
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Cochrane Risk of Bias Assessment method. 
Although several systems exist for the 
grading of clinical evidence and the creation 
of clinical practice guidelines27, GRADE 
has been widely used owing to its balance 
between simplicity and effectiveness for 
quality assessment28,29. A major difference 
in the development of the OARSI and 
ESCEO recommendations is that the 
OARSI working group performed new 
meta- analyses to inform their GRADE 
assessments, whereas ESCEO used published 
meta- analyses. For the ESCEO guidelines, 
the findings of network meta- analyses 
were assessed using GRADE only if ‘direct 
comparisons’ were performed16; the results 
from all remaining network meta- analyses 
were reported descriptively.
Selection of the expert panels
In their 2019 reports16,17, both OARSI and 
ESCEO recognize the need for input from 
multiple disciplines; thus, health- care 
providers and patient representatives 
contributed to the development of 
the respective treatment guidelines. The 
structure and the duties of the panels, 
however, differed. Firstly, the ESCEO 
working group comprised European 
members only, whereas the OARSI panels 
included members from the UK, Europe, 
Asia, North America, South America and 
Australasia.
ESCEO gathered a single panel of 
18 members comprising specialists in rheu-
matology, rehabilitation, orthopaedics, clini-
cal epidemiology, public health and health 
economics, as well as patient representatives, 
to oversee all aspects of the project; four 
individuals were tasked with conducting 
the literature search. By contrast, OARSI 
recruited a core expert panel of six members 
who supervised the project; a separate voting 
panel consisted of 13 members considered 
representative of the wider OARSI member-
ship, including specialists in rheumatology, 
orthopaedics, primary care, pharmacology, 
sports medicine, physical therapy and  
rehabilitation. In addition, a literature 
review team comprised five individuals 
with method ological expertise, and a patient 
panel comprised three patient represent-
atives who were invited to participate in 
formulating the OARSI recommendations 
during a meeting at the 2018 OARSI conven-
tion. A key difference between the task forces 
was that the OARSI literature review panel 
pre- selected specialists in statistical methods 
whereas the ESCEO panel did not; this dif-
ference is most likely attributable to the fact 
that OARSI conducted new meta- analyses 
as part of the assessment process while 
the ESCEO assessment was restricted to a  
systematic review.
Declaring competing interests
For OARSI, conflicts of interests were 
managed by adherence to OARSI Ethics 
Committee guidelines and by independent 
review of disclosures by the Ethics 
Committee. Individuals with high-level 
competing interests (for example, close 
involvement with a manufacturer of a 
product) were ineligible, whereas those with 
a lower level related to a specific intervention 
(for example, consulting) were prohibited 
from participating in discussions, evidence 
synthesis and/or review of the corresponding 
sections17. By contrast, ESCEO permitted 
panel members to participate provided they 
were transparent regarding any potential 
conflicts of interest.
Literature searches
Both the OARSI and ESCEO panels  
conducted extensive systematic reviews  
and adhered to a predefined consensus 
methodology to develop their recommen-
dations. Both systematic searches identified 
systematic reviews, meta- analyses and  
relevant randomized controlled trials. 
However, the review methodologies differed 
in some respects.
A key difference between the OARSI 
and ESCEO literature search strategies was 
that the OARSI core expert panel developed 
a list of a priori questions formulated 
using the PICO (population, intervention, 
control and outcomes) framework before 
commencement of the systematic search. 
The PICO question list consisted of  
67 knee OA- related questions focused on 
evaluating the benefits and harms of 31 non- 
pharmacological, 24 pharmacological and 
12 nutraceutical treatments. The ESCEO 
panel did not adopt PICO methodology 
prior to conducting their systematic search, 
but rather focused on the evaluation of a 
number of selected treatments in specific, 
patient- centred scenarios. Using the 
PICO framework to inform the systematic 
literature search was a key advantage of 
the OARSI guidelines methodology, as the 
development of focused clinical questions, 
modelled using the PICO framework, is 
considered the most effective approach to 
identifying high- quality evidence30 with 
data from empirical studies suggesting 
this approach yields more precise search 
results31. Furthermore, the use of PICO 
questions to evaluate the benefits and harms 
of non- surgical treatments for knee OA 
helped to ensure that the search strategy 
was patient- focused.
The OARSI and ESCEO searches 
identified relevant manuscripts in the 
Medline, EMBASE and Cochrane databases; 
the OARSI search also included PubMed, 
Google Scholar and the reference lists of 
systematic reviews and meta- analyses. 
The ESCEO panel performed a systematic 
literature search for publications from 
2014 through to 30 September 2018 using 
a combination of keywords and controlled 
search terms16; the specific terms used in 
the search strategy were not published by 
ESCEO. The aim was to identify the most 
relevant literature related to treatments 
listed in the previous 2014 guidelines6 
and any other interventions subsequently 
approved or available for the management 
of knee OA16. The OARSI literature 
review panel searched the aforementioned 
databases using search terms including, 
but not limited to, ‘osteoarthritis’, ‘arthrosis’, 
‘trial’, ‘comparative study’, ‘arthroplasty’, 
‘single- blind’ and ‘double- blind’, with no 
start date specified. In the first instance, 
a PICO- informed systematic review of the 
literature from inception to December 2017 
was performed and was later updated 
on 12 July 2018 (ref.17). By specifying 
the inclusion of ‘approved’ medications, the 
search strategy employed by the ESCEO 
panel could have yielded fewer publications 
than the OARSI strategy. More importantly, 
this restriction might have excluded 
informative data; for instance, data from 
phase 0–III trials in knee OA in which the 
medication under investigation had not yet 
been approved by the FDA or the EMA.
Both the OARSI and ESCEO teams 
screened the abstracts and full texts of the 
identified publications. When relevant data 
were available, both the ESCEO and OARSI 
teams performed ‘quality of literature’ 
assessment using the GRADE criteria to 
assign literature a score of high, moderate, 
low or very low.
Voting procedures
As part of the OARSI methodology, prior 
to panel voting, the core expert panel 
reviewed all relevant documentation 
synthesized from the systematic literature 
search and GRADE evidence tables for 
each intervention. Once this review was 
completed, the dedicated voting panel, 
which had access to all the supplementary 
background materials (including primary 
data, analyses and GRADE tables), voted 
on the recommendations formed to 
address the PICO questions. All voting on 
recommendations was done using an online, 
electronic survey system with all votes kept 
completely anonymous. All contentious 
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issues were discussed and debated in an 
online discussion forum before re- voting. 
By contrast, all members of the ESCEO 
working group were provided with  
more detailed work packages, which 
included details of the 2014 algorithm, 
selected detailed summaries of the results  
of the updated literature search (2014–2018), 
GRADE evidence tables that included 
summaries of the quality of the evidence, 
and details of the magnitude of the effect for 
each respective intervention; reference lists 
were also provided. Voting by the ESCEO 
working group was completed anonymously 
via e- mail with panellists voting on their 
recommendation for each respective 
intervention.
Both the OARSI and ESCEO working 
groups invited their voting panels to provide 
a recommendation for each question and/or  
intervention, as outlined in fig. 1. Votes 
by the panels were cast on the direction 
and strength of the recommendations. 
For the ESCEO guidelines, all treatment 
recommendations were assessed according 
to the following criteria: current and 
past evidence; balance between the 
benefits and harms of each intervention; 
magnitude of treatment effects; quality 
of the evidence; value and preferences; 
costs (informed by clinical experience and 
formal cost assessments); and the position 
of an intervention within the treatment 
algorithm16. Similarly, the OARSI 
recommendations were based on modified 
GRADE criteria, which included the criteria 
listed above as well as the assessment of 
estimates of treatment effect size, confidence 
in such estimates and clinical preference. 
Unlike the ESCEO working group, the 
OARSI panel conducted a two- stage vote. 
In the first stage, the expert panel voted on 
the inclusion or exclusion of a few selected 
interventions that were put forward by the 
expert panel; interventions that remained 
after the first stage were termed ‘core 
treatments’, defined as those appropriate 
for use in almost all patients and safe to 
use in combination with first- line and 
second- line treatments. In the second stage, 
which consisted of three voting rounds, all 
remaining interventions (including those 
that were excluded in the first stage) were 
voted on. The voting panel were asked 
to vote on the directionality (‘in favour’ 
or ‘against’) and strength (‘strong’ or 
‘conditional’) of their recommendation 
in line with modified GRADE criteria.
One of the key differences between 
the ESCEO and OARSI recommendations 
was that OARSI specified that in the event 
that no adequate evidence could be found 
for a specified intervention, the evidence 
quality score for that given intervention 
was designated as ‘very low’ by default17. 
In the event that the ESCEO panel 
members thought the available evidence 
was balanced (that is, between ‘do’ and ‘do 
not’), they could vote ‘no recommendation’. 
Of the 14 non- surgical recommendations 
proposed by ESCEO, five are ‘strong’ and 
nine are ‘weak’; the OARSI panel made nine 
‘strong’ recommendations (core treatments 
and topical NSAIDs) and 13 ‘conditional’ 
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Fig. 1 | Summary of voting procedures for the oaRSI and eSCeo working groups. This schematic illustrates the voting procedures used by the working 
groups of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the 
Osteoarthritis Research Society International (OARSI) to reach consensus on their respective recommendations for the management of knee osteoarthritis 
(OA). The OARSI panel voted in two stages. In the first stage, they voted on the inclusion or exclusion of core treatments (that is, treatments appropriate 
for use in almost all patients and safe to use in combination with first- line and stage 2 treatments). Stage 2 involved up to three rounds of voting on the 
direction and strength of all remaining interventions. Contentious issues were discussed in an online forum before re- voting. All interventions were assigned 
to one of seven levels, which determined the ordering of treatment provision and strength of the recommendations. The ESCEO panel voted on the direc-
tion and strength of proposed recommendations in a single stage of voting. All interventions were given either a strong recommendation or a weak 
recommendation. OARSI table adapted with permission from ref.17, Elsevier.
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level 1A and level 5 recommendations made 
by OARSI are ‘strong’ whereas all remaining 
recommendations are ‘conditional’ (see fig. 1).
Comparison of the recommendations
We have discussed the similarities and 
the differences in methods used in the 
development of the 2019 OARSI and ESCEO 
recommendations. Despite such differences, 
the joint OARSI–ESCEO working group 
found, as outlined in this section, that many 
aspects of the recommendations for the 
non- surgical management of knee OA are 
in agreement.
Similarities
Core treatments appropriate for use 
in the majority of patients. In both the 
OARSI and ESCEO stepwise treatment 
algorithms, patient education and/or access 
to information, exercise and weight loss 
(if a patient is overweight) should form 
the core treatment approach prior to the 
commencement of first- line and stage 2 
treatments (as shown in fig. 2)16,17. In line 
with their 2014 recommendations6, the 2019 
ESCEO recommendations endorse aerobic, 
strengthening and resistance exercises. 
Similarly, the OARSI guidelines recommend 
structured, land- based exercise programmes 
of strengthening, cardiovascular, balance 
and/or neuromuscular exercises, but also 
add mind–body exercise including Tai Chi  
and yoga. The only subtle difference 
between the two guidelines is that the 
ESCEO recommendation includes all types 
of exercise, stating that the evidence to 
differentiate between different modalities 
is not available, whereas the OARSI 
recommendation excludes aquatic exercise 
from core treatments owing to concerns 
about accessibility.
First- line treatments. Following core 
treatments, both the OARSI and ESCEO 
guidelines strongly recommend the use of 
topical NSAIDs in the first- line management 
of knee OA, owing to their proven efficacy  
and a low risk of gastrointestinal, cardio-
vascular and renal adverse effects16,17. Both 
guidelines advise against the long- term 
use of paracetamol (acetaminophen) as a 
first- line treatment for knee OA, with the 
OARSI guidelines strongly recommending 
against its use in both the short term and 
long term, and the ESCEO guidelines 
making a ‘weak’ recommendation for its 
use in the short term. Both guidelines do 
not recommend the use of supplementation 
with non- pharmaceutical grade glucosamine 
hydrochloride, glucosamine sulfate and/or 
chondroitin sulfate.
Pharmacological management of persistent 
symptoms. As a stage 2 therapy, both the 
OARSI and ESCEO guidelines recommend 
the use of oral NSAIDs in patients with 
persistent OA symptoms after the use 
of first- line treatments, personalized 
according to a patient’s gastrointestinal and 
cardiovascular risk profile16,17. Both sets 
of guidelines are in agreement that oral 
NSAIDs should only be used intermittently 
for the shortest period of time and at the 
lowest possible dose to control pain, owing to 
their known adverse cardiovascular, hepatic 
and renal effects. Specifically, for patients 
with normal gastrointestinal function both 
sets of guidelines recommend the use of 
non- selective oral NSAIDs, preferably in 
combination with a proton pump inhibitor 
(PPI), or selective cyclooxygenase 2 (COX2) 
inhibitors. In those with gastrointestinal 
complications, selective COX2 inhibitors 
and non- selective NSAIDs in combination 
with a PPI are recommended in both sets 
of guidelines, with the ESCEO guidelines 
further suggesting that celecoxib may be 
the ‘preferred’ oral NSAID16. In those with 
an increased risk of cardiovascular events, 
both the ESCEO and OARSI guidelines are 
very cautious: the former suggests limiting 
the use of COX2 inhibitors to 30 days and 
of non- selective NSAIDs to 7 days, whereas 
the latter recommends against the use of 
any oral NSAIDs in this group of patients. 
In the OARSI guidelines NSAIDs are not 
recommended for use in patients with 
frailty; the ESCEO guidelines make no such 
recommendation as this comorbidity was 
not assessed. Age is a major risk factor in its 
own right for cardiovascular, cerebrovascular 
and gastrointestinal adverse outcomes and 
should be taken into account when assessing 
the benefit- to- risk ratio of NSAID usage32,33. 
There is also evidence to suggest that age 
increases the relative risk of adverse effects of 
NSAIDs; thus, it has been recommended that 
oral NSAIDs should not be used in persons 
aged 65 years and above34. The ESCEO 
guidelines recommend the use of topical 
NSAIDs over oral NSAIDs in patients with 






































Physical assessment (as needed)
• Arthritis information and/or education
• Structured exercise programmes
• Topical NSAIDs
• Non-selective NSAIDs
• Non-selective NSAIDs with PPI
• COX2 inhibitors
• Intra-articular corticosteroids
• Aquatic exercise, gait aids,
self-management programmes
• IAHA
• CBT with exercise
ESCEO
• Arthritis information and/or education
• Structured exercise programmes
• Referral to health professionals plus
physical therapy
• SYSADOAs (pharmaceutical grade
glucosamine sulfate and/or chondroitin
sulfate)
• Low-dose, short-term paracetamol
• Topical NSAIDs for persistent symptoms
• Oral non-selective NSAIDs with PPI
• COX2-selective drugs and
non-selective NSAIDs
• Intra-articular corticosteroids and/or
IAHA
• Short-term, weak opioids
• Duloxetine
Fig. 2 | Simplified oaRSI and eSCeo treatment algorithms for the non-surgical management of 
knee oa in patients without comorbidities. The list of treatments shown conforms to the recom-
mended ordering of treatment provision in the updated 2019 guidelines for the management of knee 
osteoarthritis (OA) issued by the European Society for Clinical and Economic Aspects of Osteoporosis, 
Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Osteoarthritis Research Society 
International (OARSI). For the OARSI recommendations, physical assessments are performed as 
needed, before entry into the treatment algorithm. The treatments in stage 3 of the ESCEO algorithm 
represent the last pharmacological option before knee replacement surgery. CBT, cognitive behav-
ioural therapy; COX2, cyclooxygenase 2; IAHA, intra- articular hyaluronic acid; PPI, proton pump 
inhibitor; SYSADOAs, symptomatic slow- acting drugs for osteoarthritis.
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risk of renal adverse events; the OARSI 
guidelines make no such recommendation 
because this age group was not considered 
separately.
Both the OARSI and ESCEO guidelines 
support the use intra- articular injections of 
corticosteroids and state that this interven-
tion might be more effective in the short  
term (~2–4 weeks) than in the long term  
(≥6 weeks)16,17. Specifically, the ESCEO 
guidelines recommend the use of intra- 
articular corticosteroids in patients with 
persistent pain after first- line treatments 
and oral NSAIDs, suggesting that this 
approach is more effective in those with 
more severe pain, which might be a predic-
tor of its short- term efficacy. Similarly, the 
OARSI guidelines recommend the use of 
intra- articular corticosteroids in patients 
in whom symptom relief is not achieved 
after treatment with core treatments, topi-
cal NSAIDs and/or non- selective NSAIDs. 
Neither the OARSI nor ESCEO guidelines 
recommend the use of the presence of effu-
sion as a predictor of a positive response to 
intra- articular corticosteroids. Intra- articular 
hyaluronic acid (IAHA) is recommended 
in both guidelines. The OARSI guidelines 
conditionally recommended IAHA for all 
patients at different stages of treatment 
depending on their comorbidity profiles. For 
example, in patients with knee OA who have 
no comorbidities, IAHA is recommended 
after failure to respond to core treatments, 
topical NSAIDs and oral NSAIDs (including 
COX2 inhibitors). The ESCEO guidelines 
recommend the use of IAHA in patients with 
contraindications to NSAIDs or those who 
are still symptomatic despite use of NSAIDs.
Differences
The OARSI and ESCEO treatment algo-
rithms differ in several ways, as summarized 
in Table 2. In this section, we expand upon 
the differences in recommendations beyond 
core treatments.
First- line treatments. The ESCEO 
recommendations advise that patients should 
be referred to a physical therapist or other 
medical professional to determine if varus 
or valgus correction is needed following 
adherence to core treatments16. Alternatively, 
the OARSI guidelines recommend an initial 
physical assessment prior to entry into 
the treatment algorithm. As part of first- line 
treatment, the ESCEO and OARSI guidelines 
both recommend the use of topical NSAIDs. 
OARSI recommends their use as the first 
pharmacological intervention in all patients 
except those with chronic widespread pain 
disorder. The ESCEO guidelines, however, 
recommend topical NSAID use if painful 
symptoms persist following short- term 
rescue analgesia with paracetamol (at doses 
of no greater than 3 g per day), treatment 
with symptomatic slow- acting drugs for OA 
(SYSADOAs), which include pharmaceutical 
grade (microcrystalline) glucosamine sulfate 
and chondroitin sulfate, and physical therapy. 
Background therapy with these products is 
recommended by ESCEO prior to the use of 
topical NSAIDs based on their interpretation 
of the evidence base16,35–38, and probably 
because of the inferred excellent safety profile 
of SYSADOAs and long- lasting symptomatic 
effects. OARSI evaluated the same literature 
base and made negative recommendations 
for all glucosamine and chondroitin products 
(including pharmaceutical grade).
The ESCEO guidelines provide recom-
mendations for the use of SYSADOAs, 
including strong recommendations for 
pharmaceutical grade crystalline gluco-
samine sulfate and chondroitin sulfate 
and weak recommendations for avocado 
soybean unsaponifiables and diacerein; 
they also make a weak recommendation 
against the use of combined glucosamine 
and chondroitin sulfate. Another difference 
between the ESCEO and OARSI guidelines 
is that the former includes separate recom-
mendations for pharmaceutical grade and 
non- pharmaceutical grade products whereas 
the OARSI recommendations are generaliz-
able to all such products. The ESCEO guide-
lines provide negative recommendations 
for non- pharmaceutical grade glucosamine 
and chondroitin formulations while OARSI 
strongly recommends against the use of all 
formulations (including pharmaceutical 
grade products) because of a lack of effi-
cacy or low quality evidence and high risk 
of bias16,17.
Final pharmacological treatment before 
surgery. As the last attempt to manage 
symptoms pharmacologically before 
surgical intervention, the ESCEO guidelines 
recommend the short- term use of weak 
opioids (such as tramadol) because of their 
efficacy in relieving pain and providing 
small improvements in function. However, 
the adverse effects of these drugs, which 
include drowsiness, dizziness, nausea, 
constipation and an increase in the risk  
of falls (especially in elderly patients) are  
well known; hence, they should be used  
only for short periods of time. As an 
alternative to opioids, the ESCEO guidelines  
further recommend the use of duloxetine  
(a serotonin–norepinephrine reuptake 
inhibitor), particularly in patients with 
central pain sensitization, despite an 
increased risk of adverse events including 
dizziness and risk of falls. The OARSI 
guidelines, however, make a negative 
recommendation for the use of opioids 
owing to their unfavourable efficacy and/or 
safety profile17, and recommend duloxetine 
only for patients who have knee OA and 
widespread pain and/or depression.
Consideration of comorbidities. Both the 
OARSI and ESCEO 2019 guidelines tailor 
their treatment recommendations to specific 
comorbidities. Specifically, both include 
treatment recommendations for patients 
with knee OA who have no comorbidities 
Table 2 | Differences in oaRSI and eSCeo recommendations for the non- surgical management of knee oa
level or stage Intervention oaRSI eSCeo
First- line treatments Topical NSAIDs Recommend use as the first pharmacological 
intervention
Recommend use after short- term rescue 
analgesia with paracetamol (acetaminophen), 
SYSADOAs and physical therapy
Paracetamol Conditionally recommend against the use of 
paracetamol both in the short and long term
Recommend short- term use (≤3 g/day) and 
strongly advise against use in the long term
SYSADOAs Strongly advise against the use of all 
glucosamine and chondroitin formulations 
(including pharmaceutical grade)
Recommend the use of pharmaceutical grade 
glucosamine sulfate and chondroitin sulfate
Treatment in patients with 
persistent symptoms
Opioids Strongly recommend against the use of oral 
and transdermal opioids
Recommend the short- term use of weak opioids 
such as tramadol
ESCEO, European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; OA, osteoarthritis; OARSI, 
Osteoarthritis Research Society International; SYSADOAs, symptomatic slow- acting drugs for osteoarthritis.
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and those with or at an increased risk of 
adverse gastrointestinal and cardiovascular 
outcomes. In addition, the OARSI 
recommendations are tailored for patients 
with frailty or widespread pain and/or 
depression; the ESCEO recommendations 
are not, although they are tailored to 
those at increased risk of renal adverse 
events. The OARSI working group set out 
to evaluate treatments in the context of 
comorbidities a priori and the treatment 
recommendations were informed by the 
systematic literature searches, whereas it 
was unclear from the ESCEO manuscript 
whether making recommendations in the 
context of comorbidities was a primary 
or secondary objective. In addition, a key 
difference between the two sets of guidelines 
is that the OARSI guidelines include 
‘Good Clinical Practice Statements’ to 
accompany the recommendations, which 
were written to help support the treatment 
recommendations and were informed by 
expert experience.
Implications and perspectives
The 2019 recommendations proposed 
by OARSI and ESCEO outline two 
informative treatment algorithms for the 
non- surgical management of knee OA. 
Both sets of recommendations provide 
health- care providers with evidence- based 
and expert- reviewed advice. Overall, the 
two publications provide very similar 
recommendations, particularly with regard 
to the core treatments that all patients 
should receive. They both provide similar, 
progressive management algorithms, 
although some differences exist, particularly 
in the ordering of treatments along the 
treatment algorithm. Both attempt to 
‘personalize’ the treatment algorithms to 
patient characteristics, which is essential 
when considering the use of oral NSAIDs 
and COX2 selective inhibitors. Specifically, 
the OARSI recommendations are tailored 
for groups with particular comorbidities 
including those at increased risk of 
gastrointestinal or cardiovascular adverse 
events, those with frailty and those with 
widespread pain and/or depression. The 
ESCEO recommendations are personalized 
by considerations for gastrointestinal, 
cardiovascular, hepatic and renal risk 
and for specific age groups. Neither set of 
recommendations specifically discusses 
age as a factor by which to personalize 
treatment; however, it is likely that the 
consideration of comorbidities, especially 
frailty, partially take age into account.
The OARSI and ESCEO guidelines 
differ in their recommendations for the use 
of topical NSAIDs and SYSADOAs. The 
ESCEO guidelines recommend the use of 
pharmaceutical grade glucosamine and 
chondroitin sulfate as first- line therapies 
prior to the use of topical NSAIDs in those 
with persistent symptoms. The OARSI 
guidelines, however, strongly recommend 
against the use of all glucosamine and 
chondroitin formulations (including 
pharmaceutical grade); the OARSI 
guidelines recommend the use of topical 
NSAIDS as the first- line treatment. A 
possible explanation for the conflicting 
recommendations made by the ESCEO 
and OARSI groups regarding the use of 
glucosamine are most likely attributable 
to differences in the interpretation of the 
quality of the evidence, including risk of 
bias, and in the synthesis of that evidence 
by the expert panels. Lastly, both guidelines 
strongly recommend against the long- term 
use of paracetamol owing to its low efficacy 
and notable adverse effect profile; however, 
the ESCEO guidelines do suggest short- term 
use of doses limited to 3 g per day. Again, 
the assessment of different study literature 
could explain this difference. Specifically, in 
their updated literature search (2014–2018) 
the ESCEO panel evaluated four reviews 
and/or meta- analyses that examined 
the safety and efficacy of paracetamol, 
which covered both randomized trials 
and observational studies, whereas the 
OARSI panel examined only the results of 
five randomized trials. The ESCEO panel 
reported that while they found no evidence 
for the use of paracetamol in the short term 
as a rescue analgesic on a background of 
other treatments (for example, SYSADOAs), 
they comment that “this is its traditional 
use”16. Consequently, the recommendation 
for the short- term use of paracetamol might 
be informed more by clinical opinion than 
by the clinical evidence.
The differences in the treatment 
recommendations proposed by the 
OARSI and ESCEO working groups can 
be explained, in part, by methodological 
differences. Despite evaluating similar 
data, both groups made several different 
treatment recommendations, which 
would suggest that a degree of uncertainty 
regarding the available evidence remains. 
Hence, there is a need for more robust 
evidence.
Conclusions
Overall, the 2019 OARSI and ESCEO 
treatment algorithms for the non- surgical 
management of knee OA overlap consider-
ably, which should provide confidence and 
clarity for practising clinicians regarding 
the treatment of patients with knee OA. The 
differences between the two sets of recom-
mendations might be attributable, in part, 
to methodological issues, highlighting the 
importance of refining and harmonizing 
guideline methodology and ideally produc-
ing unified guidelines that are endorsed by 
multiple societies and non- governmental 
organizations. Furthermore, harmonization 
could be achieved through the encourage-
ment of cross- collaboration between both 
national and international organizations. 
Practising clinicians would also benefit 
from the future development of online edu-
cational programmes specifically designed 
for health- care practitioners with input 
from all the major societies and stake-
holders, with the subsequent distillation 
of a consistent set of recommendations for 
patients with OA and the lay public.
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